

**2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era**  
**Tweetorial #1 References**

**Tweet 3**

PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon- $\beta$ -1a in relapsing MS. *Neurology*. 2001;56:1628-36.  
<https://n.neurology.org/content/56/12/1628.long>

Kappos L, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018;391(10127):1263-1273.  
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)30475-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30475-6/fulltext)

**Tweet 4**

Nazareth TA, et al. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice. *Mult Scler Relat Disord*. 2018;26:219-234.  
<https://doi.org/10.1016/j.msard.2018.09.017>

**Tweet 5**

Lublin FD. New multiple sclerosis phenotypic classification. *Eur Neurol*. 2014;72(Suppl. 1):1-5.  
<https://doi.org/10.1159/000367614>

**Tweet 6**

Lublin FD. New multiple sclerosis phenotypic classification. *Eur Neurol*. 2014;72(Suppl. 1):1-5.  
<https://doi.org/10.1159/000367614>

**Tweet 8**

Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018;17(2):162-173 [https://www.thelancet.com/journals/lanneur/article/PIIS1474-4422\(17\)30470-2/fulltext](https://www.thelancet.com/journals/lanneur/article/PIIS1474-4422(17)30470-2/fulltext)

**Tweet 9**

Miller DH, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Mult Scler*. 2008;14:1157-1174.  
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850590/pdf/10.1177\\_1352458508096878.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850590/pdf/10.1177_1352458508096878.pdf)

**Tweet 11**

Langer-Gould A, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. *Arch Neurol*. 2006;63(12):1686-1691.  
<https://jamanetwork.com/journals/jamaneurology/fullarticle/792891>

## **Glossary**

ASAP, as soon as possible

CIS, clinically isolated syndrome

CNS, central nervous system

CSF, cerebrospinal fluid

DIS, dissemination in space

DIT, dissemination in time

DMT, disease-modifying therapies

dx, diagnose(d)

IFN, interferon

MRI, magnetic resonance imaging

MS, multiple sclerosis

NP, nurse practitioner

PA, physician assistant

PPMS, primary-progressive multiple sclerosis

pt(s), patient(s)

RN, registered nurse

RMS, relapsing multiple sclerosis

RRMS, relapsing-remitting multiple sclerosis

SPMS, secondary-progressive multiple sclerosis

T2, type 2

tx, treatment

Vs, versus

w/, with

W/I, within

Y, year(s)

YO, year-old